OncoImmunology (Dec 2023)
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference
- Fabiana Gregucci,
- Sheila Spada,
- Mary Helen Barcellos-Hoff,
- Nina Bhardwaj,
- Charleen Chan Wah Hak,
- Alba Fiorentino,
- Chandan Guha,
- Monica L. Guzman,
- Kevin Harrington,
- Fernanda G. Herrera,
- Jamie Honeychurch,
- Theodore Hong,
- Lorea Iturri,
- Elisabeth Jaffee,
- Sana D. Karam,
- Simon R.V. Knott,
- Constantinos Koumenis,
- David Lyden,
- Ariel E. Marciscano,
- Alan Melcher,
- Michele Mondini,
- Anna Mondino,
- Zachary S. Morris,
- Sean Pitroda,
- Sergio A. Quezada,
- Laura Santambrogio,
- Stephen Shiao,
- John Stagg,
- Irma Telarovic,
- Robert Timmerman,
- Marie-Catherine Vozenin,
- Ralph Weichselbaum,
- James Welsh,
- Anna Wilkins,
- Chris Xu,
- Roberta Zappasodi,
- Weiping Zou,
- Alexandre Bobard,
- Sandra Demaria,
- Lorenzo Galluzzi,
- Eric Deutsch,
- Silvia C. Formenti
Affiliations
- Fabiana Gregucci
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
- Sheila Spada
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
- Mary Helen Barcellos-Hoff
- Department of Radiation Oncology, School of Medicine, University of California, San Francisco, CA, USA
- Nina Bhardwaj
- Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Charleen Chan Wah Hak
- Translational Immunotherapy Team, The Institute of Cancer Research, London, UK
- Alba Fiorentino
- Department of Radiation Oncology, Miulli General Regional Hospital, Acquaviva delle Fonti, Bari, Italy
- Chandan Guha
- Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA
- Monica L. Guzman
- Division of Hematology/Oncology, Department of Medicine, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA
- Kevin Harrington
- The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, National Institute for Health Research Biomedical Research Centre, London, UK
- Fernanda G. Herrera
- Centre Hospitalier Universitaire Vaudois, University of Lausanne and Ludwig Institute for Cancer Research at the Agora Cancer Research Center, Lausanne, Switzerland
- Jamie Honeychurch
- Division of Cancer Sciences, University of Manchester, Manchester, UK
- Theodore Hong
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- Lorea Iturri
- Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, Signalisation Radiobiologie et Cancer, Orsay, France
- Elisabeth Jaffee
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
- Sana D. Karam
- Department of Radiation Oncology, University of Colorado, Aurora, CO, USA
- Simon R.V. Knott
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Constantinos Koumenis
- Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- David Lyden
- Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA
- Ariel E. Marciscano
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
- Alan Melcher
- Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK
- Michele Mondini
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
- Anna Mondino
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Zachary S. Morris
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
- Sean Pitroda
- Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL, USA
- Sergio A. Quezada
- Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK
- Laura Santambrogio
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
- Stephen Shiao
- Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- John Stagg
- Centre de Recherche du Centre Hospitalier de l’Universite de Montreal, Faculty of Pharmacy, Montreal, Canada
- Irma Telarovic
- Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
- Robert Timmerman
- Departments of Radiation Oncology and Neurosurgery, University of Texas Southwestern Medical Center, Dallas, TX, USA
- Marie-Catherine Vozenin
- Laboratory of Radiation Oncology, Radiation Oncology Service, Department of Oncology, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Ralph Weichselbaum
- Department of Radiation and Cellular Oncology, Ludwig Center for Metastases Research, University of Chicago, IL, USA
- James Welsh
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Anna Wilkins
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom, Royal Marsden Hospital, Sutton, UK
- Chris Xu
- School of Applied and Engineering Physics, Cornell University, Ithaca, NY, USA
- Roberta Zappasodi
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA
- Weiping Zou
- Departments of Surgery and Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
- Alexandre Bobard
- Gustave Roussy Cancer Campus, Villejuif, France
- Sandra Demaria
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
- Lorenzo Galluzzi
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
- Eric Deutsch
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
- Silvia C. Formenti
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
- DOI
- https://doi.org/10.1080/2162402X.2023.2222560
- Journal volume & issue
-
Vol. 12,
no. 1
Abstract
ABSTRACTFocal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.
Keywords
- dose and fractionation
- FLASH radiotherapy
- immune checkpoint inhibitors
- immunomodulators
- lymph node sparing
- tumor-associated macrophages
